MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022008174

Медицинская библиотека · Blood advances · 2023

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.

Cherng Hua-Jay J, Alig Stefan K, Oki Yasuhiro, Nastoupil Loretta J, Fayad Luis, Neelapu Sattva S, Turturro Francesco, Hagemeister Fredrick, Craig Alexander F M, Macaulay Charles W, Rodriguez Maria Alma, Lee Hun Ju, McDonnell Timothy J, Flowers Christopher R, Vega Francisco, Green Michael R, Feng Lei, Kurtz David M, Alizadeh Ash A, Davis R Eric, Westin Jason R

Клиническое исследование II фазыКлиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified regimens replacing R with obinutuzumab (O) or adding lenalidomide (L) did not result in improved outcomes; however, L and O together may enhance natural killer-cell mediated antibody-dependent cellular toxicity when paired with CHOP. Here, we report on a phase 1b/2 study of 53 patients with newly diagnosed DLBCL who received 6 cycles of LO-CHOP. The end of treatment overall and complete response rates of the 50 evaluable patients were 98% and 90%, respectively. After a median follow-up of 4.5 years, the 4-year progression free and overall survival rates were 87.4% and 91.3%, respectively. Grade 3 to 4 adverse events were experienced by 70% of patients, including neutropenia (38%), thrombocytopenia (17%), fatigue (13%), and neutropenic fever (13%). Of the 33 patients profiled with circulating tumor DNA (ctDNA) sequencing, 31 (94%) had detectable pretreatment ctDNA with cancer personalized profiling by deep sequencing, 24 (73%) were classifiable by the LymphGen classifier, and 15/20 (75%) and 12/17 (71%) patients achieved early and major molecular responses after 1 and 2 cycles, respectively. Using phased variant enrichment and detection sequencing, 16/18 evaluable patients (89%) showed no detectable ctDNA after at least 5 cycles of LO-CHOP. LO-CHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA. This trial has been registered at www.clinicaltrials.gov as NCT02529852.

Для цитирования: Cherng Hua-Jay J, Alig Stefan K, Oki Yasuhiro, Nastoupil Loretta J, Fayad Luis, Neelapu Sattva S, Turturro Francesco, Hagemeister Fredrick, Craig Alexander F M, Macaulay Charles W, Rodriguez Maria Alma, Lee Hun Ju, McDonnell Timothy J, Flowers Christopher R, Vega Francisco, Green Michael R, Feng Lei, Kurtz David M, Alizadeh Ash A, Davis R Eric, Westin Jason R. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2022008174.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.